One of the consequences of the COVID-19 crisis has been an acceleration toward the digitalisation of doctor’s meetings. In China, Tencent announced last March that the crisis has enabled them to multiply the number of registered patients by 1.6, with a total of 18 million customers in June. At first sight, it looks like a […]
The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on leadership compiled by project leader Eric Bouteiller of Cornerstone Beijing The first impression listening to CEOs and leaders […]
Of the many business developments related to the COVID-19 epidemic, none has been more dramatic than the demand for medical-grade masks. The drive to meet the global need has created a supply surge in China unlike anything in the past decade, ending in a new, multi-nation industry. As the virus continued spreading around the world, […]
In the US, a rare disease is defined as affecting 75 in every 100,000 people. In China, there is not yet a specific definition, but it is under study.
2019 is now really starting in China, with the beginning of the Year of the Pig. Everybody in the China pharma market is focusing on how the new central purchasing pilot will be deployed in the coming months. At first glance it looks familiar, with convergence with known international practices: strengthening of bidding rules, phasing […]
Healthcare in China will benefit from Important progress made in 2018 in terms of the registration and approval policy for innovative drugs.